MoonLake Therapeutics Achieves Positive Results in Phase 2 Clinical Trial; Shares Up 77%
MoonLake Immunotherapeutics (Nasdaq: MLTX) has reported positive topline results from its Phase 2 clinical trial evaluating the efficacy and safety of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS). The company’s shares rose 77% following the news.
The MIRA trial recruited 234 patients and is the first randomized, double-blind, placebo-controlled trial to use Hidradenitis Suppurativa Clinical Response (HiSCR) 75 as its primary endpoint.
HiSCR75 is a higher measure of clinical response versus the HiSCR50 measure used in other clinical trials.
MoonLake’s sonelokimab has been successfully assessed in a Phase 2b trial in 313 patients with moderate-to-severe plaque-type psoriasis in which it demonstrated a rapid and durable skin clearance. It is also currently being evaluated in a Phase 2 trial in patients with active psoriatic arthritis.
Sonelokimab continues to show a favorable safety profile, in line with the known profile of IL-17 inhibitors.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. The company’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa and psoriatic arthritis – conditions affecting millions of people worldwide with a large need for improved treatment options.